Creyon Bio, Inc. today announced a global licensing and multi-target research collaboration with Eli Lilly and Company aimed at discovering, developing, and commercializing innovative RNA-targeted oligonucleotide (oligo) therapies for a wide range of diseases. Through this partnership, Creyon will apply its proprietary, industry-first AI-powered Oligo Engineering Engine to design and optimize novel drug candidates for Lilly’s selected targets, achieving timelines previously unattainable in nucleic acid drug development.

We are excited to collaborate with Lilly to advance our AI-designed oligonucleotides, with the shared goal of delivering safer and more effective therapies for patients. This partnership represents a significant milestone for Creyon as we work to bring our RNA-targeted oligo therapy pipeline into the clinic for both rare and common diseases,” said Serge Messerlian, Chairman and Chief Executive Officer of Creyon Bio.

Creyon has developed the industry’s first and only Oligo Engineering Engine, enabling the efficient design of RNA-targeted oligo therapies by applying quantum chemistry principles—moving beyond traditional trial-and-error methods to dramatically accelerate development timelines, added Swagatam Mukhopadhyay, Co-Founder and Chief Innovation Officer.

Under the terms of the agreement, Creyon will receive a $13 million upfront payment, comprising both cash and an equity investment. Additionally, Creyon is eligible for over $1 billion in potential development and commercialization milestone payments, contingent upon the achievement of specified goals. Lilly will receive an exclusive license to lead candidates for each target, and upon reaching certain milestones, will assume responsibility for further research, development, and commercialization.

Source: https://creyonbio.com/latest-news